Giuliani, M.
Bartolini, E.
Galli, B.
Santini, L.
Lo Surdo, P.
Buricchi, F.
Bruttini, M. http://orcid.org/0000-0003-1063-2522
Benucci, B.
Pacchiani, N.
Alleri, L.
Donnarumma, D.
Pansegrau, W.
Peschiera, I.
Ferlenghi, I.
Cozzi, R.
Norais, N.
Giuliani, M. M.
Maione, D.
Pizza, M.
Rappuoli, R.
Finco, O.
Masignani, V.
Article History
Received: 19 October 2017
Accepted: 13 February 2018
First Online: 27 February 2018
Competing Interests
: All authors have declared the following interests: M.G., E.B., B.G., L.S., P.L.S., F.B., N.P., D.D., W.P., I.F., R.C., N.N., M.M.G., D.M., M.P., R.R., O.F. and V.M. were employees of Novartis Vaccines at the time of the study. B.B., M.B., L.A. and I.P. were holding a PhD studentship and collaborated with GSK at the time of the study as part of their PhD training. Following the acquisition of Novartis Vaccines by the GSK group of companies in March, 2015, M.G., E.B., B.G., L.S., P.L.S., F.B., N.P., D.D., W.P., I.F., R.C., N.N., M.M.G., D.M, M.P, R.R., O.F. and V.M. are now employees of the GSK group of companies. MB is now permanent employee of Polo GGB, Siena, Italy. LA is currently employee of Eli Lilly Italia, Florence, Italy. IP is now temporary employee of Spanish National Centre of Biotechnology (CNB), Madrid, Spain.